With the introduction of more potent P2Y12 inhibitors comes a new challenge to trauma surgeons when faced with patients taking these medications. These agents possess more reliable pharmacologic antiplatelet properties than clopidogrel, which is favorable since clopidogrel has been shown to have 25% inhibition of platelet activity in up to 30% of patients. Along with increased platelet inhibition comes increased bleeding events. With promising characteristics of decreased all-cause mortality and cardiovascular events, there has been an increase in these agents use compared to clopidogrel. Little is known about the effect of these agents when a patients is injured. Through examination of various antiplatelet agents, trauma surgeons will gain valuable knowledge when faced with patients taking these medications. Particular areas of information include comparative bleeding events between agents, monitoring for progression of bleeding events, and reversal strategy efficacy and risks. Successful completion of the study?s aims will provide clinical evidence in the management of trauma patients taking antiplatelet agents. As innovation of newer antiplatelet agents occurs, trauma surgeons must gain clinical evidence in the approach to these medications. Through this multicenter, prospective trial, valuable information will assist clinicians in the management of trauma patients taking newer P2Y12 inhibitors. To date, there are no studies examining these newer agents in trauma patients.

You may be eligible for this study if you meet the following criteria:

• Conditions: trauma
• Age: 100 years or below
• Gender: All